In children 5 to 11 yrs, 2 doses of BNT162b2 vaccine associated mainly with low-grade local adverse effects and afforded nearly 50% protection against omicron infection & symptomatic illness (lower than that seen against delta). nej.md/3AeHDjz

Jun 29, 2022 · 9:15 PM UTC · Emplifi

24
36
15
61
Replying to @NEJM
Give it 3 months until you have to do a “correction” remember like you did with pregnant women and also deleted articles. Which omicron are we talking about? Pfizer’s one? Just screenshot this and remember ALL of their names.
1
196
Replying to @NEJM
Hope those royalty checks from Pfizer and Gates are juicy
8
Replying to @NEJM
Whoa! A whopping 50%!
2
Replying to @NEJM
other observational studies now suggesting 1st-gen vaxes/boosters may shift to *negative* efficacy vs current-variant infections, after just 90 days. (eg: medrxiv.org/content/10.1101/…) against that, how useful is a study that followed vaxed for *no more than* 45 days?
2
1
1
13
🤬🤬 I wonder how many people will line up for the next series of shots
1
1
Replying to @NEJM
Very concerning re: your analytical procedures. Why did you not include prior infection as a data set? This is an incomplete analysis at best, and purposeful misdirection at worst.
1
11
Replying to @NEJM
How impressive! 😑
Replying to @NEJM
Why can't we see the data after day 50?
1
4
You can.
Replying to @OS51388957
Expert A: What shall we do? Expert B: I know, let's have a study for the period marked here👇. Expert A: Great idea👍 Data scraped by @connolly_s, from datadashboard.health.gov.il/…. The data can now be found here:github.com/stephenc/2021-isr…
Show this thread
1